Related Experiment Video

Updated: Jul 5, 2026

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
10:59

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

Published on: November 23, 2017

Impact of plasminogen activator inhibitor-1 gene polymorphisms on primary membranous nephropathy

Cheng-Hsu Chen1, Kuo-Hsiung Shu, Mei-Chin Wen

  • 1Division of Nephrology, Taichung Veterans General Hospital, Taiwan.

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|May 23, 2008
PubMed
Abstract

Insights

The 4G allele of the plasminogen activator inhibitor type 1 (PAI-1) gene is linked to worse kidney outcomes and more vascular events in patients with membranous nephropathy (MN). This suggests tailored treatment for 4G/4G genotype patients.

Area of Science:

  • Nephrology
  • Genetics
  • Cardiovascular Medicine

Background:

  • Idiopathic membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults.
  • A significant portion of MN patients develop end-stage renal disease.
  • Plasminogen activator inhibitor type 1 (PAI-1) activity is implicated in renal fibrosis progression.

Purpose of the Study:

  • To investigate the association between PAI-1 gene polymorphisms (4G/5G) and the progression of MN-related pathologies.
  • To determine if PAI-1 gene variants influence clinical manifestations and disease outcomes in MN patients.

Main Methods:

  • A cohort study involving 104 biopsy-proven MN patients and 142 healthy controls.
  • Genotyping of PAI-1 gene 4G/5G polymorphisms using allele-specific polymerase chain reaction.
  • Analysis of genotype associations with clinical parameters and MN disease progression.

Main Results:

  • No significant effect of genotype distribution on MN development.
  • MN patients with the 4G/4G genotype exhibited significantly lower creatinine clearance compared to other genotypes.
  • Increased prevalence of coronary artery disease, peripheral vascular events, and disease progression in patients with the 4G/4G and 4G/5G genotypes.

Conclusions:

  • The 4G allele of the PAI-1 gene is associated with renal deterioration in MN patients.
  • Presence of the 4G allele correlates with an increased risk of cardiovascular and other vascular events.
  • Findings highlight the need for specific treatment considerations for MN patients carrying the 4G/4G genotype.

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...